Skyrizi (Risankizumab-rzaa)

Medical Uses: Skyrizi is an interleukin-23 antagonist used for the treatment of: 

• moderate-to-severe plaque psoriasis (Ps) in adults who are recipients for systemic therapy or phototherapy.
• active psoriatic arthritis (PsA) in adults. 
• moderately-severely active Crohn’s disease (CD) in adults. 

Recommended Dosage:

Plaque Psoriasis and Psoriatic Arthritis: The recommended dosage is 150 mg given by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. 

Skyrizi injection may be administered alone or along with non-biologic disease-modifying antirheumatic drugs (DMARDs).

Crohn’s Disease: The recommended induction dosage is 600 mg given by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 360 mg given by subcutaneous injection at Week 12, and every 8 weeks thereafter. 

Obtain liver enzymes and bilirubin levels before initiating therapy with Risankizumab-rzaa injection. Avoid injecting into areas where the skin is tender, erythematous, bruised, indurated or affected by psoriasis. Administration of this medicine in the upper, outer arm may only be performed by a health specialist or caregiver. 

In case any dose is missed, administer as soon as possible. Thereafter, resume dosing at the standard scheduled time.

• Use of risankizumab-rzaa injection is restricted in those with a known history of serious hypersensitivity reaction to this pharmaceutical medicinal product or any of the excipients. 
• Skyrizi injection may increase the probability of infections. Treatment with this drug should not be started in those with any clinically essential active infection until the infection resolves or is adequately treated. If a patient develops such an infection or is not responding to standard therapy, monitor them closely and do not use Skyrizi until the infection resolves.
• Assess patients for tuberculosis (TB) infection prior to starting treatment with skyrizi 150 mg. Monitor patients for signs/symptoms of active TB during and after treatment. It is not advisable to administer this medicine to those with active TB. 
• Do not use live vaccines in those treated with Risankizumab-rzaa. Medicines that interact with the immune system may increase the probability of infection following use of live vaccines. Prior to starting this therapy, complete all age-apt vaccinations as per the current immunization guidelines. 
• Severe hypersensitivity reactions, including anaphylaxis, may occur with use of skyrizi 75 mg or with any other existing dosage strength. In case a serious hypersensitivity reaction occurs, discontinue therapy and initiate apt treatment immediately. 
• In the event of drug overdose, monitor the patient for any signs/symptoms of side effects and administer apt symptomatic treatment promptly.

What documents are required to import SKYRIZI to India?

SKYRIZI (Risankizumab-rzaa) Injection can be imported by patients or government hospitals on the name of the patients only. The following documentation is required to import the product:

1. Valid prescription from a qualified doctor.
2. Patients’ diagnostic reports.
3. Patients’ ID proof (issued by the government of India).

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription from the doctor.
• Import permit if applicable.

Is SKYRIZI available in India?

SKYRIZI (Risankizumab-rzaa Injection) is a prescription drug that legally requires a medical prescription to be dispensed.

Urgent Meds helps import cancer medicines on the named patient supply (NPS). Urgent Meds is the facilitator providing input on:

• Availability of SKYRIZI in India (Ahmedabad, Mumbai, Kolkata, Hyderabad, Chennai, Delhi, Bangalore, Pune, etc.).
• Medicine Price.
• Finding genuine and reliable sources from Canada, Europe, USA, and Australia.
• Ensuring 100% transparency.

SKYRIZI can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

Urgent Meds can facilitate the supply of SKYRIZI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +16478184196 for SKYRIZI injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is able to source the SKYRIZI (Cancer Treatment Medicines) from across the globe and has the ability to supply. Urgent Meds offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Skyrizi®?

Risankizumab-rzaa is the Generic Name for the trade name drug Skyrizi®.

What is the Manufacturer’s Name of Skyrizi®?

Skyrizi® is manufactured by AbbVie Inc.

Is Skyrizi® approved by the FDA?

Yes, Skyrizi® is approved by the FDA. Date of first/initial approval: April 23, 2019.

What is the dosage and form of Skyrizi® supplied?

Skyrizi® is supplied as Injection: 150 mg/mL in each single-dose prefilled pen, 150 mg/mL & 75 mg/0.83 mL in each single-dose prefilled syringe for subcutaneous use.

What are the most common side effects with Skyrizi®?

The most common side effects with Skyrizi® include:

• Plaque Psoriasis and Psoriatic Arthritis: tinea infections, upper respiratory infections, injection site reactions, headache, and fatigue.
• Crohn’s Disease: upper respiratory infections, headache, and arthralgia (Induction), arthralgia, injection site reactions, abdominal pain, pyrexia, anemia, back pain, arthropathy, and urinary tract infection (Maintenance).

How much does Skyrizi® cost in India?

The Skyrizi 150 mg injection cost in India is reasonable. To procure this interleukin-23 antagonist authentically, you can call or WhatsApp +16478184196.

What are the storage conditions of Skyrizi®?

Store in a refrigerator at 2-8°C (36-46° F). Neither freeze nor shake. Keep prefilled pens and syringes in the original cartons to protect them from light.

Is it safe to buy Skyrizi® online in India?

Yes, you can buy Skyrizi injection online in India at the best price from Urgent Meds if Skyrizi® has not been approved or is not available in your country.